Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. - Wikidata - wikimedia - TriplyDB

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

http://www.wikidata.org/entity/Q42112490

about

Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Mechanisms of drug resistance: daptomycin resistance Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria Novel formulations for antimicrobial peptides Treatment of Gram-positive infections in critically ill patients Origin and proliferation of multiple-drug resistance in bacterial pathogens Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus Antimicrobial Activity of Cationic Antimicrobial Peptides against Gram-Positives: Current Progress Made in Understanding the Mode of Action and the Response of Bacteria Prevalence of veterinary antibiotics and antibiotic-resistant Escherichia coli in the surface water of a livestock production region in northern China Strain Dependent Genetic Networks for Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-Genome A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.Tuning the properties of the bacterial membrane with aminoacylated phosphatidylglycerol.Looking toward basic science for potential drug discovery targets against community-associated MRSA Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.Host-guest chemistry of the peptidoglycan Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.Molecular typing and phenotype characterization of methicillin-resistant Staphylococcus aureus isolates from blood in Taiwan Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.The evolutionary history of amino acid variations mediating increased resistance of S. aureus identifies reversion mutations in metabolic regulators Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.Mechanisms of antibiotic resistance in Staphylococcus aureus.Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.Chitosan augments photodynamic inactivation of gram-positive and gram-negative bacteria Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure.Genetics of antimicrobial resistance in Staphylococcus aureus.In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.

P2860

Q22305769-074097EB-0CAA-4657-8319-9535E6B1B1C4 Q24646677-EFD8B0BD-B5B0-4920-B26D-45EA432F45AC Q26779944-5DA25B7D-C720-41DA-A117-204F42ED75A9 Q26853465-5DB36935-BEE0-405D-8C7E-905ECB2712C5 Q26853612-30A5044B-970F-4620-938E-27B8D5C7A1E0 Q26863225-DF152C24-9FEC-498A-9CC8-A5C35F995CBC Q26991771-958571AF-EAD8-4D11-8A38-4CFA91B93F8A Q27015976-7DD6737C-558F-4C83-AB0C-C65437FE450B Q27023284-C29DE7FD-08A6-4260-9760-647E431BBDE9 Q27027412-E8F7FD1E-8D00-46C0-8CD8-439E8C381E64 Q28072687-31096B46-F7CD-44A2-9DB1-E9BA453EEB48 Q28544729-BC1E2C6F-0733-4CA4-BA48-3A4DFB75E587 Q28553946-E967674D-8100-4423-BBA7-E7C6D34BCC8C Q30455758-3BACB11B-3B52-4CBE-B7AE-6C0DF48EA4F6 Q31131146-4586C0BA-EACC-4544-924B-B97A53D1877D Q33507347-F76BCF5F-24FE-48DB-B7D5-C2D590927584 Q33560722-2161EF98-6623-43B9-8A59-037C5517EE3D Q33762805-CF2E38B0-150D-48EF-A691-D1D4CF681198 Q33997671-8D74B01B-80CE-4CAC-B6D7-C353F5D0286D Q34013593-5A04869A-01AA-49DA-9C9D-3702A561D92D Q34045376-70428D0C-5CC2-4C49-95E5-6823D038F216 Q34057324-D58EE183-B1CD-46E3-9600-7CCD1E836007 Q34116509-FC2F8F14-910A-4020-9466-AC7B112EA13F Q34130471-48097A3A-14EB-4B12-961B-72AA7E8F7B47 Q34146036-A1DE384A-70A6-44C2-9B1E-2B3C3FC78D75 Q34157657-3CDA733A-DF11-4712-AE2C-05E5A13CB7AA Q34278802-553AC3FF-C7CB-4B45-8613-7C89493A36B2 Q34529075-CD28E11B-6FE4-49DE-B2FF-CCF320B78CFD Q34592835-9AD6E19B-0432-4842-B5C4-BF4A42968D3D Q34630593-8BB3C863-0236-4069-AF0E-9328ADD87AC0 Q34657311-168F5BF2-63E9-4C41-AF88-33FAFF6F1937 Q34779009-6F33196A-F234-4FF2-B042-EFC6132A137B Q34932454-D06B5A46-5528-42DD-87FE-6EC57129FF4D Q34932588-7C051E4E-6564-4683-BBE5-B75ED9821D6B Q34984662-D25C1606-C80D-401A-94F6-7D774100D291 Q35023234-31788A03-D5D4-4F61-A14D-7FC96AD188AD Q35096905-DA98EC97-AD09-4D49-A788-6FE161C80179 Q35139449-12DD3B22-5930-4152-B97F-C989F50E4FDC Q35191417-1D22E514-6870-4F78-92F7-656C06C74C10 Q35191555-BEA22012-C3C4-4DEE-AAD0-6E39C0B8F32A

P2860

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

http://www.wikidata.org/entity/Q42112490

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Correlation between Reduced Da ...... mediate Staphylococcus aureus.

@en

Correlation between Reduced Da ...... mediate Staphylococcus aureus.

@nl

type

label

Correlation between Reduced Da ...... mediate Staphylococcus aureus.

@en

Correlation between Reduced Da ...... mediate Staphylococcus aureus.

@nl

prefLabel

Correlation between Reduced Da ...... mediate Staphylococcus aureus.

@en

Correlation between Reduced Da ...... mediate Staphylococcus aureus.

@nl

P1433

Q42112490-A78F677C-CAA7-4179-B183-31AA36B8E280

P1476

Q42112490-FAB2FAB6-D1AF-434F-9A1D-E4C1DB46D559

P2093

Q42112490-1A1FD3BC-92EA-461D-BF13-8F90C9E3B0D5

Q42112490-3360D1E8-CD73-4D03-9A01-C62B1AC38114

Q42112490-F468B088-BAC6-434E-B2E9-937AD9B8D15E

P2860

Q42112490-003FF995-E833-49ED-994C-5D62B760EE7B

Q42112490-09ED4B17-7565-4B43-8037-A2AD584E6217

Q42112490-10E12F9F-0FBB-4552-8624-C75D02B15ACD

Q42112490-160DCBCF-795A-4E03-8967-DF6FCE1548C4

Q42112490-192BD0B3-D9EC-4210-809C-8941CB299F5A

Q42112490-340C81DD-80E6-41FB-9250-8E415485370A

Q42112490-47FD019D-8C70-4DBF-8E53-8D01D99C7953

Q42112490-493739F9-06EF-4448-AEA5-0BB8EBF07609

Q42112490-5B40ED85-7F81-49D6-B76B-8D4BB6E949FE

Q42112490-608D66C3-6AEC-4184-A663-2F1359BB012E

P304

Q42112490-FD2C4E31-926C-4C55-9D94-4AA3F9514DCB

P31

Q42112490-1A408B97-20E4-463E-A51D-A575210CE8C2

P356

Q42112490-341AFA23-8A39-44E1-8728-478DA5C2D96A

P407

Q42112490-9201A13F-459B-4BC3-8365-16C29DC0D3F8

P433

Q42112490-286A74AD-2811-4902-A3A7-8754DE3CF3A2

P478

Q42112490-A30F0F2C-0FC6-4BA2-A3AA-73A5BA2F6867

P50

Q42112490-315C8ACC-7DE5-4042-BB3D-6022D2515818

P577

Q42112490-DD9D3E3D-4CAB-49C1-8EC5-1FAF09019C42

P698

Q42112490-226145FB-F069-4B77-B93D-EF7724719018

P932

Q42112490-701B934B-D4F7-4454-9177-72DE6CBCDF90

P356

AAC.50.3.1079-1082.2006

P1433

Antimicrobial Agents and Chemotherapy

P1476

Correlation between Reduced Da ...... rmediate Staphylococcus aureus

@en

P2093

Eiji Tominaga

http://www.w3.org/2001/XMLSchema#string

Keiichi Hiramatsu

http://www.w3.org/2001/XMLSchema#string

Longzhu Cui

http://www.w3.org/2001/XMLSchema#string

P2860

DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.

Vancomycin-resistant enterococci.

In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

The emergence and evolution of methicillin-resistant Staphylococcus aureus.

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus

Daptomycin dose-effect relationship against resistant gram-positive organisms

Daptomycin: a new drug class for the treatment of Gram-positive infections.

P304

1079-1082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.50.3.1079-1082.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16495273

http://www.w3.org/2001/XMLSchema#string

P932

1426436

http://www.w3.org/2001/XMLSchema#string